

A Bill to Regulate the Price of Insulin

BE IT ENACTED BY THE CONGRESS HERE ASSEMBLED THAT AS OF JANUARY 1ST
2024

Section 1 The price of insulin should not surpass what is considered reasonable and affordable.
Insulin in the United States should be affordable to diabetics as it is a necessity .

Section 2. The following words are defined in relation to insulin and its cost

- a. Reasonable is defined as price set in consideration of COLA (cost of living adjustment)
as well as common judgment.
- b. Affordable is defined as inexpensive and reasonably priced
- c. Companies cannot inflate the price charged for 0.3 mL of Insulin (one cartridge) more
than 15% of the production to shelf price.
- d. Product to shelf price is defined as the storage, loss, transportation and manufacturing
cost associated with the journey from a manufacturing plant to a consumer.

Section 3. The department overseeing this bill is the FDA (Food and Drug Administration).

Failure to meet standards will result in a fine consistent with triple the surcharge of said insulin
sold by the company. Failure to comply may additionally result in up to one year jail time for a
companies CEO or other officials if found guilty of intentionally raising prices above set limit.

Section 4. This legislation will take effect on January 1, 2024. All laws in conflict with this
legislation are hereby declared null and void